Michael Carleton

VP, Translational Medicine

Michael has over 20 years of experience in the pharmaceutical/biotech industry where he has held leadership roles in preclinical and clinical drug development. Prior to Inipharm, Michael was Vice President of Translational Medicine at Mavupharma until its acquisition by Abbvie. As Director of Translational Medicine at Bristol Meyers Squibb, Michael led clinical oncology biomarker programs, and his team established elevated serum IL-8 is associated with reduced clinical benefit to immune checkpoint blockade. Michael also led research groups at Presage Biosciences and Matrix Genetics, and at Merck he led the Niraparib biomarker program prior to drug out licensing to Tesaro and its successful commercialization. Michael obtained his PhD in microbiology from the University of Texas at Austin, was a CRI postdoctoral fellow, and recently served as Senior Scientific Director at The Mark Foundation for Cancer Research.